Drug reference
denosumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
Monoclonal antibody that specifically targets RANKL; binds to RANKL and inhibits its binding to RANK receptor, thereby preventing osteoclast formation; this results in decreased bone resorption and increases bone mass in osteoporosis; in solid tumors with bony metastases, RANKL inhibition decreases tumor-induced bone destruction and SREs
Common side effects
- Nausea
- Fatigue/asthenia
- Back pain
- Extremity pain
- Hypophosphatemia
Related conditions
Frequently asked questions
What drug class is denosumab?
denosumab belongs to: Oncology.
How does denosumab work?
Monoclonal antibody that specifically targets RANKL; binds to RANKL and inhibits its binding to RANK receptor, thereby preventing osteoclast formation; this results in decreased bone resorption and increases bone mass in osteoporosis; in solid tumors with bony metastases, RANKL inhibition decreases tumor-induced bone destruction and SREs
What are the common side effects of denosumab?
Nausea, Fatigue/asthenia, Back pain, Extremity pain, Hypophosphatemia
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.